Eli Lilly acquires biotech firm in new insulin venture

A new form of insulin drugs at Protomer Technoloigies caught the eye of Eli Lilly, which has bought the firm for a sum that could surpass USD 1bn (DKK 6.3bn).

Photo: Mike Blake/REUTERS / X00030

US pharmaceutical company Eli Lilly has entered into an agreement to acquire biotech company Protomer Technologies for a price that could total more than USD 1bn. The final figure will be dependent on future performance and milestone payments.

Protomer Technologies owns a peptide and protein platform which can identify and measure substances including glucose.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs